All You Need to Know About MS&AD Insurance Group (MSADY) Rating Upgrade to Buy
https://www.zacks.com/stock/news/2332338/all-you-need-to-know-about-ms-ad-insurance-group-msady-rating-upgrade-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2332338
Sep 05, 2024 - MS&AD Insurance Group (MSADY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Are Investors Undervaluing MS&AD Insurance Group (MSADY) Right Now?
https://www.zacks.com/stock/news/2332055/are-investors-undervaluing-ms-ad-insurance-group-msady-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2332055
Sep 05, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
0
Morgan Stanley (MS) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2331749/morgan-stanley-ms-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2331749
Sep 04, 2024 - In the most recent trading session, Morgan Stanley (MS) closed at $100.15, indicating a +0.89% shift from the previous trading day.
0
JPMorgan & Others Face Probe Over Interest in Cash Sweep Accounts
https://www.zacks.com/stock/news/2330396/jpmorgan-others-face-probe-over-interest-in-cash-sweep-accounts?cid=CS-ZC-FT-analyst_blog|industry_focus-2330396
Sep 02, 2024 - JPM, MS, WFC, RJF, BAC and others are under legal scrutiny for transferring clients' idle funds into sweep accounts with near-zero interest rates.
0
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
https://www.zacks.com/stock/news/2330244/sny-s-ms-drug-meets-goal-in-one-phase-iii-study-misses-in-two-others?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2330244
Sep 02, 2024 - Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
0
Sanofi drug misses primary endpoint in two trials for relapsing MS
https://seekingalpha.com/news/4145900-sanofi-drug-misses-primary-endpoint-in-two-trials-for-relapsing-ms?source=feed_sector_healthcare
Sep 02, 2024 - Sanofi's MS drug tolebrutinib did not meet primary endpoint in relapsing MS studies, but showed promise for non-relapsing secondary progressive MS.
0
Are You Looking for a High-Growth Dividend Stock?
https://www.zacks.com/stock/news/2329808/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2329808
Aug 30, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes? Let's find out.
0
Morgan Stanley (MS) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2328585/morgan-stanley-ms-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2328585
Aug 28, 2024 - Morgan Stanley (MS) closed at $102.20 in the latest trading session, marking a +0.12% move from the prior day.
0
Why Morgan Stanley (MS) is a Great Dividend Stock Right Now
https://www.zacks.com/stock/news/2322178/why-morgan-stanley-ms-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2322178
Aug 14, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes? Let's find out.
0
PRA Group's (PRAA) Q2 Earnings Beat on Strong Portfolio Income
https://www.zacks.com/stock/news/2317316/pra-group-s-praa-q2-earnings-beat-on-strong-portfolio-income?cid=CS-ZC-FT-analyst_blog|earnings_article-2317316
Aug 06, 2024 - PRA Group's (PRAA) second-quarter results reflect increased cash collections from the United States and Europe, partly offset by elevated compensation and employee services costs.
0